High Speed Angiography (HSA) at 1000 fps is a novel interventional-imaging technique that was previously used to visualize changes in vascular flow details before and after flow-diverter treatment of cerebral aneurysms in in-vitro 3D printed models. In this first pre-clinical work, we demonstrate the use of the HSA technique during flow-diverter treatment of in-vivo rabbit aneurysm models. An aneurysm was created in the right common carotid artery of each of two rabbits using previously published elastase aneurysm-creation methods.
View Article and Find Full Text PDFProc SPIE Int Soc Opt Eng
February 2024
Background: Middle meningeal artery (MMA) embolization is a promising intervention as a stand-alone or adjunct treatment to surgery in patients with chronic subdural hematomas. There are currently no large animal models for selective access and embolization of the MMA for preclinical evaluation of this endovascular modality. Our objective was to introduce a novel in vivo model of selective MMA embolization in swine.
View Article and Find Full Text PDFBackground: Several translational animal models have been described assessing intra-arterial (IA) treatments for malignant gliomas. We describe the first endovascular animal model that allows testing of IA drug delivery as a first-line treatment, which is difficult to do in actual patients. We report a unique protocol for vascular access and IA delivery in the rat model that, unlike prior reports, does not require direct puncture and opening of proximal cerebrovasculature which carries risk of ischemia in the animal brain post-delivery.
View Article and Find Full Text PDFBackground: Infarct volume measured from 2,3,5-triphenyltetrazolium chloride (TTC)-stained brain slices is critical to stroke models. In this study, we developed an interactive, tunable, software that automatically computes whole-brain infarct metrics from serial TTC-stained brain sections.
Methods: Three rat ischemic stroke cohorts were used in this study (Total = 91 rats; Cohort 1 = 21, Cohort 2 = 40, Cohort 3 = 30).